Immunosuppressants
[Immunosuppressants]
EPTIS Ringversuch Nr. 1615923 | Letze Änderung 2026-09-24 | URL: https://www.eptis.bam.de/pts1615923 https://www.eptis.bam.de/pts1615923
| Name des Anbieters | |||||||||||||||||||
| Name des Anbieters | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | ||||||||||||||||||
| Ansässig in | United Kingdom | ||||||||||||||||||
| Sprache(n) | English | ||||||||||||||||||
| Anmerkungen | Provides EQA coverage and analytical assessment for the Therapeutic drug monitoring of Whole Blood Immunosuppressants: Ciclosporin, Tacrolimus, Sirolimus, Everolimis and Serum Mycophenolate. The Scheme distributes a number of manipulated and endogenous specimens covering a wide concentration range for all analytes. Seperate Specimens are provided for each Immunosuppressant (except for Ciclosporin and Tacrolimus which share the same Specimen). | ||||||||||||||||||
| Klassifizierung | |||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
||||||||||||||||||
| Technische Einzelheiten | |||||||||||||||||||
|
|||||||||||||||||||
| Ringversuchsziele | |||||||||||||||||||
| Zielgruppe des Ringversuchs | Clinical Chemistry Public & Private Labs | ||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043:2023 | ||||||||||||||||||
| Weitere Ziele | Post market surveillance of testing methods | ||||||||||||||||||
| Teilnehmerzahl | |||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043:2023 |
||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||||||||||||||
| Kosten | |||||||||||||||||||
| Teilnahmegebühr | Contact provider for current fee, which depends on location and extent of service required. | ||||||||||||||||||
| Regelmässig durchgeführt | Ja (Monthly (11 per year)) | ||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2017 | ||||||||||||||||||
| Kontaktdaten des Anbieters | |||||||||||||||||||
| Anbieter | Kontaktperson | ||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Telefon: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Telefon: +44 121 414 7300 Fax: E-Mail: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.